

F. No. Enforc-11021(11)/46/2025-eoffice
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Enforcement & Intelligence Cell)

FDA Bhawan, Kotla Road
New Delhi-110002

Dated:

21 AUG 2025

Subject: Alert on theft of multiple drug products of M/s Novo Nordisk during transit-reg


M/s Novo Nordisk has informed about a theft of its products, as mentioned below, during transit from its Bhiwandi Hub to milk route (Nagpur, Raipur, Cuttack, and Kolkata). The products under consideration are rDNA origin injectables which are required to be stored at 2-8°C. The quality of the products may be compromised if the products are not handled in proper storage conditions since the formulations are supposed to be maintained at 2°C to 8°C failing which, would impact the quality of the product and in turn impact the safety of the patients. The matter is currently under investigation by the Police.

S. No.	Name of the product	Batch No.
1.	Insulin degludec/ Insulin Aspart (r-DNA origin) solution for injection (Ryzodeg™ FlexTouch®)	RT6GY96
2.	Insulin aspart (r-DNA Origin), solution for injection (Fiasp® Penfill®)	RR726A8
3.	Insulin aspart (r-DNA Origin), solution for injection (Fiasp® FlexTouch®)	RP5P640
4.	Semaglutide Injection 0.5mg (r-DNA Origin), solution for injection (Wegovy® FlexTouch®)	RP5S233
5.	Semaglutide Injection 0.25mg (r-DNA Origin), solution for injection (Wegovy® FlexTouch®)	RP5S232
6.	Semaglutide Injection 1 mg (r-DNA Origin), solution for injection (Wegovy® FlexTouch®)	RP5S210

Based on the above, the following advisory is provided:

- **Doctors and Healthcare professionals**
 - Carefully prescribe and educate the patients for reporting of any ADRs.
- **Patients and consumers**
 - To be careful and procure the above products from authorized sources only and with proper invoice.
- **Regulatory authorities (All state/UT Drugs Controllers and Zonal/Sub-Zonal offices of CDSCO)**

- Instruct your officers to keep a strict vigil on the movement of the said products in the market and initiate necessary action under the provisions of Drugs & Cosmetics Act, 1940 and Rules made thereunder


(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (I)

Copy to:

1. All State/UT Drugs Controllers
2. All Zonal/Sub-Zonal offices of CDSCO
3. AIOCD through email aiocd@aiocd.com
4. JS(R), Drugs Regulation Section, MoHFW, Nirman Bhawan, New Delhi
5. CDSCO-IT cell for publication on website for general public